September 12, 2024Open Access

Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, has recently been used in autoimmune diseases. We assessed the efficacy and safety of telitacicept in immunoglobulin A nephropathy (IgAN) patients.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Wang et al. (Thu,) studied this question.

synapsesocial.com/papers/68e58a69b6db643587526b27 https://doi.org/https://doi.org/10.1093/ckj/sfae285

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Telitacicept Treatment Refractory Lupus Nephritis: A Case Report2024 · 5 citations
2Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study2021 · 19 citations
3IgA Nephropathy: Core Curriculum 20212021 · 332 citations
4Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial2023 · 140 citations
5The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression2012 · 249 citations

Me gusta

Guardar

Ver artículo completo